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96Objective: This study reviews a single institution experience with the Freedom SOLO (Sorin Group, Saluggia,
Italy) aortic bioprosthesis.
Methods: Between October 2006 and February 2010, 128 patients (64 men, 64 women; mean age, 75.8  5.1
years) underwent aortic valve replacement using the Freedom SOLO stentless aortic valve. The follow-up time
was 36.7  1.2 months and 100% complete.
Results: Concomitant procedures were performed in 77 patients (60%). The mean standard European System
for Cardiac Operative Risk Evaluation was 9  2.7. Grade 3 aortic stenosis was present in 73% of patients,
mixed aortic stenosis and regurgitation were present in 40% of patients, and mitral regurgitation was present
in 46% of patients. The mean crossclamp time was 53  12 minutes for isolated Freedom SOLO aortic valve
implantation and 80 28 minutes for concomitant procedures, and the mean cardiopulmonary bypass time was
103 31 minutes. The mean implanted valve size was 22.6 1.4 mm. The mean intensive care unit and hospital
stays were 2.4  1.1 days and 8.8  2.6 days, respectively. Three patients underwent reoperation for bleeding.
The 15-day, 30-day, and perioperative mortality were all 4.6%. The 36-month survival was 95.4%  1.6% for
the cohort with a low European System for Cardiac Operative Risk Evaluation (<9) and 88.6%  1.7% for the
cohort with a high European System for Cardiac Operative Risk Evaluation (>9). Echocardiographic data pre-
operatively, immediately postoperatively, and at 3, 6, and 12 months postoperatively showed peak transvalvular
gradients of 75  23, 17  6, 18  6.5, 16  6, and 16  9 mm Hg, respectively (P<.001), and a mean left
ventricular end-diastolic diameter of 51  7, 50  6, 48  8, 47  6, and 46.5  7.5 mm, respectively
(P<.05). There were only 3 cases of early mild aortic regurgitation (grade 1), which remained stable at 12
months.
Conclusions: The Freedom SOLO stentless aortic valve has excellent early and intermediate-term results.
(J Thorac Cardiovasc Surg 2013;146:96-102)Aortic valve replacement (AVR) using a stentless biopros-
theses usually requires 2 separate suture lines for correct
and exact fixation in the aortic root. As a result, increased
crossclamp time is required compared with that required
for stented bioprostheses. The Freedom SOLO (Sorin
Group, Saluggia, Italy) (Figure 1) aortic valve is a stentless
pericardial valve prosthesis that is made of 2 sheets of peri-
cardium with no fabric reinforcement and that requires only
1 suture line.1 As are all stentless bioprostheses, the Free-
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The Journal of Thoracic and Cardiovascular Surgehemodynamics, improved transvalvular gradients, left ven-
tricular reverse remodeling, increased orifice areas, and
possibly better survival compared with other earlier gener-
ations of stented pericardial bioprostheses.2-5 This is
important, especially in sicker patients with reduced left
ventricular function and various types of comorbidities.
Since the Freedom SOLO was introduced in 2004, it has
been increasingly used, but still little is known of the
intermediate-term results. This single-center study reports
our experience with the Freedom SOLO aortic valve to as-
sess the early and intermediate-term results of a consecutive
series of 128 patients.
MATERIALS AND METHODS
Study Population
From October 2006 to February 2010, 128 consecutive patients under-
went AVRwith the Freedom SOLO aortic valve. The indication for surgery
was aortic valve stenosis or regurgitation or mixed lesions. Implantation of
the Freedom SOLO valvewas carried out by the same experienced surgeon
for the whole series. Aortic valve pathology is listed in Table 1. The study
population had a mean age of 75.8  5.1 years (range, 55-86 years),
and 50% (64 patients) were male. The mean body surface area was
1.7  0.2, mean standard European System for Cardiac Operative Riskry c July 2013
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
IVS ¼ interventricular septum
LVEDD ¼ left ventricular end-diastolic
diameter
LVESD ¼ left ventricular end-systolic
diameter
NYHA ¼ New York Heart Association
PW ¼ posterior wall
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DEvaluation (euroSCORE) was 9 2.7, and mean logistic euroSCORE was
15.9  12.8. Sinus rhythm was present in 81.3% of patients, and atrial fi-
brillation was present in 15% of patients. Twenty-four patients (18.7%)
were in New York Heart Association (NYHA) class I, 71 patients
(55.4%) were in NYHA class II, 30 patients (23.4%) were in NHYA class
III, and 3 patients (2.3%) were in NYHA class IV. Twenty-one patients
(16.4%) had a low preoperative euroSCORE (defined as a standard euro-
SCORE<9), and 107 patients (83.6%) had a high euroSCORE (defined
as a standard euroSCORE>9). Preoperative risk factors (Table 2) were cor-
onary heart disease in 64.8% (83 patients), arterial hypertension in 93%
(119 patients), diabetes mellitus in 35.9% (46 patients), renal dysfunction
in 18.8% (24 patients), hypercholesterolemia in 68% (87 patients), and
pulmonary hypertension in 14.8% (19 patients). Six patients (4.7%) had
undergone prior cardiac surgery. Preoperative medications in the whole se-
ries consisted of beta-blockers in 46.9% of patients, angiotensin-
converting enzyme inhibitors in 34.4% of patients, angiotensin inhibitors
in 8.6% of patients, aldosterone antagonists in 7% of patients, diuretics
in 41.7% of patients, digoxin in 10.2% of patients, calcium channel
blockers in 35.2% of patients, statins in 48.4% of patients, platelet inhib-
itors in 64% of patients, and warfarin (Sintrom, Novartis, Greece) antico-
agulants in 9.4% of patients. Preoperative echocardiographic left
ventricular end-diastolic diameter (LVEDD) was 50.9  7.2 mm, left ven-
tricular end-systolic diameter (LVESD) was 33.7  9.8 mm, ejection frac-
tion was 53.8%  12.8% (range, 25%-75%), fractional shortening was
33.4%  10%, posterior wall (PW) thickness was 11.8  1.9 mm, inter-
ventricular septum (IVS) thickness was 12.3  2 mm, right ventricular
end-diastolic diameter was 26.3  6.9 mm, left atrium was 43.2  6
mm, and aortic root was 32.6  5.1 mm. Preoperative pulmonary artery
systolic pressure was 43.3  12.8 mm Hg, peak flow velocity was 4.05
 1.09 ms, peak transaortic gradient was 75.3  23.5 mm Hg, and mean
transaortic gradient was 48.8 15.8 mm Hg. The main outcome measures
were early and late mortality, echocardiographic data in all patients imme-
diately postoperatively (defined as 3 days after the operation) and 3, 6, and
12 months postoperatively, and incidence of complications.
Operative Technique
Isolated AVR was performed in 51 patients (39.8%), and concomitant
procedures were performed in 77 patients (60.2%), which consisted of cor-
onary artery bypass grafting in 72 patients (56.3%), mitral valve replace-
ment in 8 patients (6.3%), tricuspid valve repair in 3 patients (1.5%),
and pulmonary valve replacement in 1 patient (0.8%). Concomitant proce-
dures were performed before valve implantation with the exception of
proximal anastomosis of the saphenous vein or radial artery grafts, which
were performed after the implantation and before aortic declamping. After
induction of general anesthesia, a median sternotomy was performed and
mild hypothermic (32C) cardiopulmonary bypass (CPB) was instituted.The Journal of Thoracic and CAfter aortic crossclamping, a transverse aortotomy was performed 0.5 to
1 cm above the sinotubular junction and intermittent cold cardioplegia
was administered via the coronary ostia, followed by thorough resection
of the leaflets and annular decalcification. The size of the implant was de-
termined by measuring the diameter of the aortic annulus with the appro-
priate sizer provided by the manufacturer. Patients with annuloaortic
ectasia were excluded from the study. Annuloaortic ectasia was defined
as dilation of the aortic root and ascending aorta tapering to a normal cal-
iber at the origin of the innominate artery. The Freedom SOLO aortic valve
should not be used in cases of porcelain aorta due to native severe aortic
calcification. Complete decalcification of the annulus is important before
valve implantation, because a heavily calcified aortic root could impede
the placement of the sutures.
In every case, the Freedom SOLO aortic valve was implanted using 3
continuous single sutures (4-0 polypropylene) in the supra-annular posi-
tion, starting at the deepest point of each sinus of Valsalva just above the
top of the corresponding commissures and placed 3 to 4 mm apart from
the annulus. On completion, the 3 suture lines were tied outside the aortic
wall, with no need for reinforcement. Valve sizes 21, 23, 25, and 27 mm
were implanted in 47 patients (36.7%), 57 patients (44.5%), 23 patients
(18%), and 1 patient (0.8%), respectively. The mean implanted valve
size was 22.65  1.48 mm. The median implanted valve size was 23
mm. After aortotomy closure, de-airing, and release of the crossclamp,
the patient was weaned from CPB. Intraoperative transesophageal echocar-
diographic evaluation of the correct opening of the valve leaflets and con-
firmation of absence of paravalvular leak and aortic regurgitation greater
than trivial were performed before CPB weaning and transfer to the inten-
sive care unit. Routine anticoagulation after chest tube removal was applied
only in patients with postoperative atrial fibrillation, because oral anticoa-
gulation is not the routine for bioprostheses at Athens Medical Center. All
patients received subcutaneous low-molecular-weight heparin until hospi-
tal discharge. All patients received lifelong antiplatelet therapywith aspirin
(100 mg/d).
Statistical Analysis
Data are expressed as percentages, means standard deviations, or me-
dians with ranges as appropriate. One-way repeated-measures analysis of
variance with the Bonferroni multiple comparison test was used to assess
the influence of time on cardiac dimensions and transvalvular gradients
and velocities. The a value for the Bonferroni test was set at 0.05. Overall
survival was determined using Kaplan–Meier curve analysis. SPSS soft-
ware (17.0 for Windows, SPSS Inc, Chicago, Ill) was used.RESULTS
Operative Data, Mortality and Morbidity, and
Survival
The mean crossclamp time was 52.7  11.9 minutes for
isolated Freedom SOLO aortic valve implantation and 80.4
 28.3 minutes for concomitant procedures, and the mean
CBP time was 103.2  31.2 minutes. Mean intensive care
unit and hospital stays were 2.4  1.1 days and 8.8  2.6
days, respectively. Three patients required reoperation for
bleeding.
All patients survived the operation. The 30-day mortality
was 4.6% (n ¼ 6). None of these deaths were related to
valve complications or dysfunction. Two patients died of
cardiogenic shock, 2 patients died of multiorgan failure,
and 2 patients died of hemorrhage. All of them had a high
standard euroSCORE (>9). The 2 patients who died of
bleeding had undergone early reoperation for possibleardiovascular Surgery c Volume 146, Number 1 97
FIGURE 1. Survival of patients with low versus high euroSCORE who underwent Freedom SOLO (Sorin Group, Saluggia, Italy) AVR. euroSCORE,
European System for Cardiac Operative Risk Evaluation; SE, standard error; ES, euroSCORE.
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Dsurgical correction, but no potential source could be identi-
fied. On return to the cardiac intensive care unit, every pos-
sible effort was undertaken to reverse coagulopathy with
transfusion of fresh-frozen plasma and fibrinogen, but with-
out success, and the patients died. Patient follow-up was
100% complete for a mean of 36.7  1.2 months. There
were 4 late deaths in our series (3.2%), 2 due to heart failure
and 2 due to non–valve-related cerebrovascular accident.
There were no cases of reoperation for endocarditis, valve
thrombosis, or structural valve degeneration. None of our
patients required a pacemaker implant. The actuarial sur-
vival was 92.9%  1.2% at 24 months and 91.4% 
2.3% at 36 months for the entire series. After comparing
survival in patients with low versus high euroSCORE, the
survivals were 95.4% 1.6% at 24 months in the low euro-
SCORE subgroup, which remained stable at 36 months, and
91.3%  1.8% at 24 months and 88.6%  1.7% at 36
months in the high euroSCORE cohort. Early andTABLE 1. Frequency of different aortic valve pathologies in 128
patients undergoing aortic valve replacement with the Freedom
SOLO (Sorin Group, Saluggia, Italy) valve
Aortic valve pathology N %
Aortic stenosis
 Mild 6 4.7
 Moderate 15 11.7
 Severe 93 72.7
Aortic regurgitation
 Mild 31 24.2
 Moderate 27 21.1
 Severe 8 6.3
Mixed aortic pathology 51 39.8
Bicuspid aortic valve 3 2.3
98 The Journal of Thoracic and Cardiovascular Surgeintermediate-term survival of the 2 cohorts is shown in
Figure 1. There were no statistically significant differences
in the survivals between the 2 groups (P ¼ not significant).Hematologic Data
Minimum postoperative hematocrit, hemoglobin, plate-
let, and red blood cell counts were 27.6%  3%, 8.9  1
g/dL, 71.6  41.7/mL, and 3.1 3 106  403.8 3 104/mL,
respectively, the high euroSCORE cohort versus 38.1% 
5.1%, 12.4  1.8 g/dL, 229.9  74.5/mL, and 4.3 3 106
 713.9 3 104/mL, respectively, in the low euroSCORE
cohort (all P<.01). Only 1 of our patients had severe throm-
bocytopenia with a platelet number less than 30,000/mL.
Minimum platelet number was observed 3.51  1.17 days
(median day, 3) after the operation. Mean autologous red
blood cell transfusion units and fresh-frozen plasma units
were 3.5  2.2 units and 5.6  3.2 units, respectively.
None of our patients required platelet transfusion, including
the 3 patients who underwent reoperation for bleeding.TABLE 2. Preoperative risk factors for the entire cohort of 128
patients
N %
Coronary heart disease 83 64.8
Arterial hypertension 119 93
Diabetes mellitus 46 35.9
Renal dysfunction 24 18.8
Hypercholesterolemia 87 68
Pulmonary hypertension 19 14.8
Prior cardiac surgery 6 4.7
Urgent cases 30 23.5
Elective cases 98 76.5
ry c July 2013
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DHemodynamic Data
Left ventricular ejection fraction was 53.8%  12.8%,
59.3%  15.1%, 55.7%  10.2%, 56.2%  10.7%, and
53.9%  11.1% preoperatively, at discharge, and at 3, 6,
and 12 months postoperatively, respectively, in the entire
cohort after AVR.
The LVEDD, LVESD, IVS thickness, and PW thickness
preoperatively, postoperatively, and at 3-, 6-, and 12-month
follow-ups are shown in Table 3. LVEDD reduction was sig-
nificant during the follow-up (F ¼ 2.93, P<.05); the Bon-
ferroni test showed a significant difference between
postoperatively and 12 months (P < .05). Reduction of
IVS was significant during follow-up (F ¼ 2.77, P<.05);
the Bonferroni test showed a significant difference between
postoperative IVS and IVS at both 6 and 12 months
(P<.05).
LVESD changes and PW reduction during the follow-up
could be due to chance, and no significant differences be-
tween the follow-up intervals were found on the Bonferroni
test.
Peak and mean gradients postoperatively and at 3-, 6-,
and 12-month follow-ups are shown in Table 3. Peak and
mean gradient reduction during follow-up was significant
(F ¼ 3.50, P<.001 and F ¼ 3.21, P<.05, respectively);
the Bonferroni test showed a significant difference between
postoperatively and 3, 6, and 12 months (P<.05). Values of
peak velocity as depicted in Table 2 showed a significant re-
duction during follow-up (F ¼ 2.17, P<.001); the Bonfer-
roni test showed a significant difference between early
postoperatively and 6 months (P<.001).
LVEDD, LVESD, IVS thickness, PW thickness, and peak
and mean gradients per valve size are shown in Table 4 in
regard to preoperative, postoperative, and 3-, 6-, and 12-
month follow-up values. In 21-, 23-, and 25-mm valves,
LVEDD reduction was significant during follow-up
(F ¼ 3.89, P< .05; F ¼ 4.54, P< .05; and F ¼ 3.01,
P<.05, respectively). The Bonferroni test showed a signif-
icant difference between immediately postoperatively and
12 months in all of these valve sizes (P<.05). For the 27-
mm valve, statistical analysis was not applicable because
of a single value.TABLE 3. Comparison of echocardiographic data postoperatively and at 3,
variance
Preoperative Postoperative
LVEDD (mm) 50.9  7.2 49.6  6.2
LVESD (mm) 33.7  9.8 33  7.9
IVS (mm) 12.3  2 12.3  2
PW (mm) 11.8  1.9 10.8  1.8
Peak gradient (mm Hg) 75.3  23.5 16.8  5.6
Mean gradient (mm Hg) 48.8  15.8 10.6  3.6
Peak velocity (cm/sec) 4.1  1.2 1.8  0.4
LVEDD, Left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diam
The Journal of Thoracic and CLVESD reduction was not significant for 21- and 25-mm
valves, but it was significant for the 23-mm valve (F¼ 5.01,
P< .05). The Bonferroni test showed a significant differ-
ence between postoperatively and 12 months (P< .05).
For the 27-mm valve, statistical analysis was not applicable
because of a single value.
PW reduction was not significant for 23- and 25-mm
valve sizes, but it reached statistical significance in the
21-mm size (F¼ 3.99, P<.05). The Bonferroni test showed
a significant difference between postoperatively and both 6
and 12 months of follow-up (P<.05). For the 27-mm valve,
statistical analysis was not applicable because of a single
value.
IVS reduction was significant for the 21-, 23-, and 25-mm
valves (F ¼ 2.87, P<.05; F ¼ 3.62, P<.05; and F<4.21,
P<.05). The Bonferroni test showed a statistically signifi-
cant difference between postoperatively and both 6 and 12
months for the 21- and 23-mm valves but only between
postoperatively and 12 months for the 25-mm valves. For
the 27-mm valve, statistical analysis was not applicable be-
cause of a single value.
The mean gradient reduction during follow-up was sig-
nificant for the 21-, 23-, and 35-mm valves (F ¼ 7.34,
P<.05; F ¼ 5.21, P<.05; and F ¼ 3.39, P<.05, respec-
tively). The Bonferroni test showed a statistically signifi-
cant difference between postoperatively and 3, 6, and 12
months (P<.05). For the 27-mm valve, statistical analysis
was not applicable because of a single value.
Peak gradient reduction during follow-up was significant
for valve sizes 21, 23, and 35 mm (F ¼ 3.19, P< .001;
F ¼ 4.72, P<.001; and F ¼ 5.56, P<.001, respectively).
The Bonferroni test showed a statistically significant differ-
ence between postoperatively and 3, 6, and 12 months
(P< .05). For the 27-mm valve, statistical analysis was
not applicable because of a single value.
Thromboembolism, Endocarditis, Reoperation, and
Structural Valve Dysfunction
There were no episodes of thromboembolism, endocardi-
tis, valve reoperation, or structural valve dysfunction during
the follow-up time.6, and 12-month follow-ups bymeans of repeated-measures analysis of
3 mo 6 mo 12 mo P value
48.4  8.3 47.2  5.7 46.5  7.5 <.05
32  7.7 31.3  6.1 31.1  9.3 NS
11.4  1.6 11  1.6 10.8  1.3 <.05
10.6  1 10.3  1 10.2  1.4 NS
16.1  6.5 16  6.3 15.9  9.1 <.001
10.2  1.6 10.1  1 10  2.9 <.05
1.8  0.2 <.001
eter; IVS, interventricular septum; PW, posterior wall; NS, not significant.
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TABLE 4. Comparison of echocardiographic data postoperatively and at 3-, 6-, and 12-month follow-ups by means of repeated-measures analysis
of variance stratified by valve size
Preoperative Postoperative 3 mo 6 mo 12 mo P value
21 mm (n ¼ 47)
LVEDD (mm) 47.9  6.9 46.2  6.1 45.2  6.2 45  3.8 45.1  4.6 <.05
LVESD (mm) 30.4  8.7 31.5  7.6 30.9  4.6 28.5  6.1 30.1  2.3 NS
IVS (mm) 12.6  2.1 11.8  1.5 11  1.7 10.3  1.5 10.8  1.3 <.05
PW (mm) 12.1  2.1 11.6  1.4 10.5  1.4 10.3  1.1 10.2  1.4 <.05
Peak gradient (mm Hg) 75.4  21.8 20.5  7.6 20.2  5.9 16.9  7.6 15.9  8.3 <.001
Mean gradient (mm Hg) 46.3  15.7 9.3  2.2 9  1.6 9.1  1 9  2.9 <.05
23 mm (n ¼ 57)
LVEDD (mm) 50.7  11.1 50.1  5.4 50.4  5.9 49  5 48.5  7.9 <.05
LVESD (mm) 33  9.1 32.2  8.4 32.7  5.9 33  4.8 29.9  5.6 <.05
IVS (mm) 12.3  1.89 11.4  1.8 11.4  1.6 10.9  1.1 10.8  0.9 <.05
PW (mm) 11.8  1.9 10.8  1.9 10.9  1.4 10.9  1.3 10.9  1 NS
Peak gradient (mm Hg) 74.9  25.8 16.5  6.3 16.4  6.7 16.1  5.6 13.4  7.4 <.001
Mean gradient (mm Hg) 52.2  16.1 10.1  4.6 9.4  2.1 9.2  1.4 7.6  5 <.05
25 mm (n ¼ 23)
LVEDD (mm) 57.4  9.1 54.1  6 54.2  3.9 50  7.1 45.8  10.4 <.05
LVESD (mm) 33  9.4 32.9  6.9 32.2  7.3 31.9  5.3 31.5  2.3 NS
IVS (mm) 11.7  2.1 11.5  1.8 10.9  1.3 10.8  1,2 10.5  1.9 <.05
PW (mm) 11.2  1.6 11.3  0.7 11  1 10.9  1.1 10.9  2.1 NS
Peak gradient (mm Hg) 74.2  19.6 12.7  2.5 12  2 11.9  4 11.4  0.9 <.001
Mean gGradient (mm Hg) 38.4  12.1 10  2.9 9.4  1.3 7  4.5 5.1  3.9 <.05
27 mm (n ¼ 1)
LVEDD (mm) 52 50 48 48 48 N/A
LVESD (mm) N/A N/A N/A N/A N/A N/A
IVS (mm) 11.5 11.4 11 11 11 N/A
PW (mm) 11.6 11.5 11 11 11 N/A
Peak gradient (mm Hg) 103 14 13 13 13 N/A
Mean gradient (mm Hg) 55 9 8 7 7 N/A
LVEDD, Left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVS, interventricular septum; PW, posterior wall; N/A, not applicable.
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DNonstructural Valve Disease
Early nonstructural valve dysfunction with mild (grade I)
intravalvular aortic regurgitation was found in 3 patients,
which remained stable during the follow-up time, and the
patients were clinically asymptomatic. No clinically signif-
icant hemolysis was observed in the absence of valve
dysfunction.DISCUSSION
Stentless bioprostheses for AVR have been considered
over the traditional stented bioprostheses because the
stentless xenograft resembles and provides flow character-
istics equivalent to an aortic homograft and similar to the
normal human aortic valve.6 Both inflow and outflow su-
tures are excluded from the blood path, and by eliminating
a rigid sewing ring in the annulus, the dynamic nature of
the aortic root is preserved. The nonturbulent flow, with
extremely low transvalvular gradients, mitigates thrombo-
embolism or prosthetic valve endocarditis, and formal an-
ticoagulation is unnecessary. This reduced propensity for
valve-related events has been confirmed by clinical expe-
rience. As aortic valve prosthesis design has evolved, the100 The Journal of Thoracic and Cardiovascular Surgdevelopment of new stented valves has significantly re-
duced the hemodynamic differences between them and
their stentless counterparts, except for patients with
a small aortic annulus.7,8 This is of extreme importance
when calcific aortic valve stenosis with a small annulus,
which is prevalent in the elderly, is taken into
consideration, because this population is at higher risk
for patient–prosthesis mismatch. The Freedom SOLO
bioprosthesis is a pericardial stentless valve with
a design and implantation technique that make it an
ideal choice for AVR in this population.
The current article reviews our first 128 consecutive cases
with the Freedom SOLO bioprosthesis, and to the best of
our knowledge, this is the first early and intermediate-
term report of this type of prosthesis, especially in 2 euro-
SCORE groups (low vs high).
The simplified supra-annular subcoronary technique of
implantation using a single running suture translates into
a shorter mean crossclamp time and total CBP time. These
times are comparable to those reported by Aymard and col-
leagues.9 This is a major benefit for our study population be-
cause the majority are high-risk patients with a standard
euroSCORE greater than 9. Despite the recently reportedery c July 2013
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Dearly dysfunction of a large Freedom SOLO valve,10 we did
not encounter such a problem in our series. Despite the ab-
sence of an annular anchoring suture line or set of sutures
that could have a detrimental impact on valve stability or
motion, regular echocardiographic follow-up in our study
did not demonstrate any structural valve degeneration.
Moreover, no form of aneurysm developed in any of our pa-
tients in regular follow-up echocardiographic studies,
which is a strong indicator that the outer ring abuts the aor-
tic annulus well enough to prevent ejection of blood into the
dead-end space below the coronet suture line. Because two
thirds of our patients were aged 75 years or more, more than
75% had a standard euroSCORE greater than 9, and given
the high risk nature of these patients, the incidence of com-
plications was considered low.
In regard to the hemodynamics of the Freedom SOLO bi-
oprosthesis, peak and mean transvalvular gradients and
peak velocity have been shown to correlate as well as those
of other bioprostheses.5,11-14 In our study population,
81.2% of patients had a prosthesis size of 21 or 23 mm.
Fear of patient–prosthesis mismatch has been reported to
be increased as the diameter of the aortic annulus
decreases,15 and the Freedom SOLO valve seems to show
excellent results in this group of patients.
The potential survival benefits of stentless valves may re-
late to the early regression of left ventricular hypertrophy
and normalization of left ventricular function.16,17
Experience shows regression of left ventricular
hypertrophy after valve replacement with most prosthesis
types.18 However, comparative studies show that for me-
chanical valves and stented bioprostheses, the regression
of left ventricular hypertrophy never reaches baseline
levels.19,20 In contrast, aortic homografts and stentless
xenografts allow rapid and complete resolution of left
ventricular hypertrophy.16,21 In our series, LVEDD and
IVS were reduced significantly between preoperative
evaluation and follow-up. LVESD and PW also decreased,
but this reduction was not statistically significant.
In 2008, a significant decrease in platelet count was
reported in several cases in the early postoperative
period after valve replacement with the Freedom SOLO
prosthesis,22 which was also observed by other surgical
teams.23-25 The data analyzed in our series showed
a significant decrease in the platelet numbers compared
with preoperative values, which occurred 3.5  1.5 days
(median day, 3) after the operation, as well as a decrease
in hemoglobin, hematocrit, and red blood cell numbers.
Nonetheless, in our study, only 1 patient experienced
severe thrombocytopenia, and none of our patients
required platelet transfusion.
Complete decalcification of the annulus is important be-
fore valve implantation, because a heavily calcified aortic
root could impede the placement of the sutures. In patients
in whom this is not technically feasible or severeThe Journal of Thoracic and Camalformation of the annulus is present, it is preferable to
avoid implantation of the Freedom SOLO bioprosthesis to
avoid valve deformation and thus dysfunction. In our series,
aneurysms of the suture line did not develop in any of our
patients on follow-up echocardiographic evaluation.
Study Limitations
This is a single-center study that shares all the limitations
of a retrospective study. Because life expectancy in those
high-risk patients is low, survival decreases with time
independently of valve-related events, which impedes
follow-up. Moreover, echocardiographic evaluation was
not performed by the same physician. Data from an appro-
priate control group of stented bioprostheses are currently
being processed and will be reported in the future but
were unavailable during this study. In addition, pulse-
duplicator data for potential valve durability estimates are
also unavailable.
CONCLUSIONS
The Freedom SOLO stentless bioprosthesis seems to be
an adequate option for AVR, especially in older and criti-
cally ill patients with comorbidities. Early and
intermediate-term hemodynamics assessed by echocardiog-
raphy proved to be excellent even in patients with a small
aortic annulus, which could make the Freedom SOLO bio-
prosthesis the best choice in this subgroup. Nevertheless,
these data must be reconfirmed by other studies and supple-
mented by long-term data.
References
1. Beholz S, Claus B, Dushe S, Konertz W. Operative technique and early hemody-
namic results with the Freedom Solo valve. J Heart Valve Dis. 2006;15:429-32.
2. Jin XY, Gibson DG, Yacoub MH, Pepper JR. Perioperative assessment of aortic
homograft, Toronto stentless valve, and stented valve in the aortic position. Ann
Thorac Surg. 1995;60(2 Suppl):S395-401.
3. Konertz WF. Stentless aortic xenograft heart valves. Asian Cardiovasc Thorac
Ann. 2003;11:1-2.
4. Ali A, Halstead JC, Cafferty F, Sharples L, Rose F, Coulden R, et al. Are stentless
valves superior to modern stented valves? A prospective randomized trial.Circu-
lation. 2006;114(1 Suppl):I535-40.
5. BorgerMA, Carson SM, Ivanov J, Rao V, Scully HE, Feindel CM, et al. Stentless
aortic valves are hemodynamically superior to stented valves during mid-term
follow-up: a large retrospective study. Ann Thorac Surg. 2005;80:2180-5.
6. Sintek CF, Fletcher AD, Khonsari S. Stentless porcine aortic root: valve of choice
for the elderly patient with small aortic root? J Thorac Cardiovasc Surg. 1995;
109:871-6.
7. Chambers JB, Rimington HM, Hodson F, Rajani R, Blauth CI. The subcoronary
Toronto stentless versus supra-annular Perimount stented replacement aortic
valve: early clinical and hemodynamic results of a randomized comparison in
160 patients. J Thorac Cardiovasc Surg. 2006;131. 878-2.
8. de Kerchove L, Glineur D, El Khoury G, Noirhomme P. Stentless valves for aor-
tic valve replacement: where do we stand? Curr Opin Cardiol. 2007;22:96-103.
9. Aymard T, Eckstein F, Englberger L, Stalder M, Kadner A, Carrel T. The Sorin
Freedom SOLO stentless aortic valve: technique of implantation and operative
results in 109 patients. J Thorac Cardiovasc Surg. 2010;139:775-7.
10. Caprili L, Fahim AN, Zussa C, Cristell DM. Very early malfunction of a large
stentless aortic valve. Eur J Cardiothorac Surg. 2009;36:417-8.
11. Chambers JB, Rimington HM, Rajani R, Hodson F, Shabbo F. A randomized
comparison of the Cryolife O’Brien and Toronto stentless replacement aortic
valves. J Thorac Cardiovasc Surg. 2007;133:1045-50.rdiovascular Surgery c Volume 146, Number 1 101
Acquired Cardiovascular Disease Iliopoulos et al
A
C
D12. D’Onofrio A, Auriemma S, Magagna P, Favaro A, Cannarella A, Piccin C, et al.
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis:
7 years’ experience in 130 patients. J Thorac Cardiovasc Surg. 2007;134:491-5.
13. Peteiro J, Campos VV, Valle J, Alvarez N, Castro-Beiras A. Hemodynamic com-
parison by Doppler echocardiography of valves in the aortic position: value of the
continuity equation to assess prosthetic dysfunction. Echocardiography. 1998;
15:325-36.
14. Beholz S, Repossini A, Livi U, Schepens M, El Gabry M, Matschke K, et al. The
Freedom SOLO valve for aortic valve replacement: clinical and hemodynamic
results from a prospective multicenter trial. J Heart Valve Dis. 2010;19:115-23.
15. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation.
1978;58:20-4.
16. Del Rizzo DF, Goldman BS, Christakis GT, David TE. Hemodynamic benefits of
the Toronto stentless valve. J Thorac Cardiovasc Surg. 1996;112:1431-46.
17. Jin XY, Pillai R, Westaby S. Medium-term determinants of left ventricular
mass index after stentless aortic valve replacement. Ann Thorac Surg. 1999;
67:411-6.
18. Monrad ES, Hess OM,Murakami T, Nonogi H, CorinWJ, Krayenbuehl HP. Time
course of regression of left ventricular hypertrophy after aortic valve replace-
ment. Circulation. 1988;77:1345-55.
19. De Paulis R, Sommariva L, Colagrande L, De Matteis GM, Fratini S, Tomai F,
et al. Regression of left ventricular hypertrophy after aortic valve replacement102 The Journal of Thoracic and Cardiovascular Surgfor aortic stenosis with different valve substitutes. J Thorac Cardiovasc Surg.
1998;116:590-8.
20. Thomson HL, O’Brien MF, Almeida AA, Tesar PJ, Davison MB, Burstow DJ.
Haemodynamics and left ventricular mass regression: a comparison of the stent-
less, stented and mechanical aortic valve replacement. Eur J Cardiothorac Surg.
1998;13:572-5.
21. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implica-
tions of echocardiographically determined left ventricular mass in the Framing-
ham Heart Study. N Engl J Med. 1990;322:1561-6.
22. Yerebakan C, Kaminski A, Westphal B, Kundt G, Ugurlucan M, Steinhoff G,
et al. Thrombocytopenia after aortic valve replacement with the Freedom Solo
stentless bioprosthesis. Interact Cardiovasc Thorac Surg. 2008;7:616-20.
23. Hilker L,WodnyM, Ginesta M,Wollert HG, Eckel L. Differences in the recovery
of platelet counts after biological aortic valve replacement. Interact Cardiovasc
Thorac Surg. 2009;8:70-3.
24. Piccardo A, Caus T. eComment: Lower postoperative platelet levels after aortic
valve replacement with Freedom Solo prostheses: are there clinical repercus-
sions? Interact Cardiovasc Thorac Surg. 2009;8:73.
25. Yerebakan C, Westphal B, Steinhoff G, Liebold A. eComment: Freedom Solo
stentless aortic bioprosthesis and postoperative thrombocytopenia—interpreta-
tion of available data and clinical consequences for surgeons. Interact Cardio-
vasc Thorac Surg. 2009;8:73-4.ery c July 2013
